Obscure Pill Burned Fat Without Muscle Loss or Weight Rebound of Ozempic

Key Points:

• Researchers have identified TOFA, a decades-old oral compound, that reduces obesity by increasing cellular energy burn rather than suppressing appetite, showing an average 18% weight loss in obese mice without muscle loss or reduced food intake.
• TOFA works by blocking fat production enzymes and activating gene regulators that enhance fat burning, increasing energy expenditure by about 18% without raising body temperature, which suggests a safe metabolic boost.
• When combined with existing injectable drugs like semaglutide (Ozempic) or tirzepatide, TOFA enhanced fat loss, blood sugar control, and lipid profiles more effectively than either drug alone, also preserving muscle mass and providing longer-lasting weight loss after treatment cessation.
• TOFA also improved fatty liver disease markers in mice without causing the triglyceride increases seen with similar drugs, indicating potential benefits for obesity-related liver conditions without added cardiovascular risk.
• Though promising, TOFA has only been tested in male mice so far, with human safety and dosing yet to be established; some study authors have financial interests in related drug development, highlighting the need for cautious interpretation and further research.